Anti-human immunodeficiency virus type 1 (HIV-1) CD8+ T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency

Journal of Virology

Volumn 74, Issue 9, 2000, Pages 4127-4138

  Rinaldo Jr , Charles R ^a,b   Huang, Xiao Li ^a   Fan, Zheng ^a   Margolick, Joseph B ^c   Borowski, Luann ^a   Hoji, Aki ^a   Kalinyak, Christine ^a   Mcmahon, Deborah K ^a,b   Riddler, Sharon A ^a,b   Hildebrand, William H ^d   Day, Richard B ^a   Mellors, John W ^a,b,e  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INDINAVIR; LAMIVUDINE; T LYMPHOCYTE ANTIBODY; ZIDOVUDINE;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; DRUG THERAPY, COMBINATION; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; INTERFERON TYPE II; LAMIVUDINE; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; PEPTIDES; PHENOTYPE; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIRAL MATRIX PROTEINS; ZIDOVUDINE;

EID: 0343183221     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.9.4127-4138.2000     Document Type: Article

References (56)

1. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:6103-6110.
3. Brander, C., W. J. Pichler, and G. Corradin. 1995. Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine. Clin. Exp. Immunol. 101:107-113.
4. Bryant, J., R. Day, T. L. Whiteside, and R. B. Herberman. 1992. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods 146:91-103.
5. Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. Quantitative analysis of the human immunodeficiency virus type (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
6. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active ART. Proc. Nat. Acad. Sci. USA 94:13193-13197.
7. Dalod, M., M. Dupuis, J. C. Deschemin, D. Sicard, D. Salmon, J. F. Delfraissy, A. Venet, M. Sinet, and J. G. Guillet. 1999. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 73:7108-16.
8. Dalod, M., M. Harzic, I. Pellegrin, B. Dumon, B. Hoen, D. Sereni, J. C. Deschemin, J. P. Levy, A. Venet, and E. Gomard. 1998. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J. Infect. Dis. 178:61-69.
9. De Maeyer, E., and J. De Maeyer-Guignard. 1998. Interferons, p. 491-516. In A. Thomson (ed.), The cytokine handbook. Academic Press, New York, N.Y.
10. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
11. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active ART. Science 278:1295-1300.
12. - lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J. Virol. 70:2022-2026.
13. Furtado, M. R., D. S. Callaway, J. P. Phair, K. J. Kunstman, J. L. Stanton, C. A. Macken, A. S. Perelson, and S. M. Wolinsky. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New Engl. J. Med. 340:1614-1622.
14. + repertoire during antiviral therapy. Nat. Med. 4:215-221.
15. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162: 1780-1788.
16. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, L. Jonas, A. Meibohm, D. Holder, W. A. Schleif, J. H. Condra, E. A. Emini, R. Isaacs, J. A. Chodakewitz, and D. D. Richman. 1998. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280:35-41.
17. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior ART. N. Engl. J. Med. 337:734-739.
18. + cytotoxic Tcells express CD38 and HLA-DR antigens. J. Immunol. 150:3070-3079.
19. Huang, X. L., Z. Fan, J. Liebmann, and C. Rinaldo. 1995. Detection of human immunodeficiency virus type 1-specific memory cytotoxic T lymphocytes in freshly donated and frozen-thawed peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 2:678-684.
20. + T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clin. Diagn. Lab. Immunol. 7:279-287.
21. Kalams, S. A., S. P. Buchbinder, E. S. Rosenberg, J. M. Billingsley, U. S. Colbert, N. G. Jones, A. K. Shea, A. K. Trocha, and B. D. Walker. 1999. Association between virus-specific cytoloxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J. Virol. 73:6715-6720.
22. Kalams, S. A., P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg, and B. D. Walker. 1999. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73:6721-6728.
23. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188: 2199-2204.
24. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keet, J. K. Eeftinck-Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specitic cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365-1372.
25. Koup, R., J. Safrit, Y. Cao, C. Andrews, G. McLeod, W. Borkowskj, C. Farthing, and D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
26. + memory T cells. J. Exp. Med. 186:859-865.
27. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:8055-8063.
28. + virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:103-110.
29. McMichael, A. J., and R. E. Phillips. 1997. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15:271-296.
30. Musey, L., J. Hughes, T. Schacker, T. Shea, L. Corey, and M. J. McElrath. 1997. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337:1267-1274.
31. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, A. Hurley, M. Markowitz, D. D. Ho, D. F. Nixon, and A. J. McMichael. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
32. Ogg, G. S., X. Jin, S. Bonhoeffer, P. Moss, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones. A. Hurley, M. Markowitz, D. D. Ho, A. J. McMichael, and D. F. Nixon. 1999. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73:797-800.
33. Ogg, G. S., S. Kostense, M. R. Klein, S. Jurriaans, D. Hamann, A. J. McMichael, and F. Miedema. 1999. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J. Virol. 73:9153-9160.
34. + T-cell responses. Immunol. Lett. 66:77-80.
35. Ortiz, G. M., D. F. Nixon, A. Trkola, J. Binley, X. Jin, S. Bonhoeffer, P. J. Kuebler, S. M. Donohoe, M.-A. Demoitie, W. M. Kakimoto, T. Ketas, B. Clas, J. J. Heymann, L. Zhang, Y. Cao, A. Hurley, J. P. Moore, D. D. Ho, and M. Markowitz. 1999. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active anti-retroviral therapy. J. Clin. Investig. 104:RI3-R18.
36. Pakker, N. G., D. W. Notermans, R. J. de Boer, M. T. Roos, F. de Wolf, A. Hill, J. M. Leonard, S. A. Danner, F. Miedema, P. and T. Schellekens. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat. Med. 4:208-214.
37. Parker, K. C., M. A. Bednarek, L. K. Hull, U. Utz, B. Cunningham, H. J. Zweerink, W. E. Biddison, and J. E. Coligan. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J, Immunol. 149:3580-3587.
38. Pontesilli, O., S. Kerkhof-Garde, D. W. Notermans, N. A. Foudraine, M. T. Roos, M. R. Klein, S. A. Danner, J. M. Lange, and F. Miedema. 1999. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J. Infect. Dis. 180:76-86.
39. Pontesilli, O., M. R. Klein, S. R. Kerkhof-Garde, N. G. Pakker, F. deWolf, H. Schuitemaker, and F. Miedema. 1998 Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant Gag-specific response is associated with nonprogressive infection. J. Infect. Dis. 178:1008-1018.
40. Rasmussen, L., S. Morris, D. Zipeto, J. Fessel, R. Wolitz, A. Dowling, and T. C. Merigan. 1995. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J. Infect. Dis. 171:177-182.
41. Richman, D. 1999. The challenge of immune control of immunodeficiency virus. J. Clin. Investig. 104:677-678.
42. Richman, D., S. Crowe, and K. Harvey. 1999. HIV viral load monitoring. Adv. Exp. Med. Biol. 458:199-212.
43. Riddell, S. R., and P. D. Greenberg. 1995. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 113:545-586.
44. + T cell numbers in progression of HIV-1 infection. AIDS Res. Hum Retrovir. 14:1423-1433.
45. Rinaldo, C., X. L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Coltrill, and P. Gupta. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
46. Rinaldo, C. R., Jr., J. M. Liebmann, X.-L. Huang, Z. Fan, Q. Al-Shboul, D. K. McMahon, R. D. Day, S. A. Riddler, and J. W. Mellors. 1999. Prolonged suppression of human immunodeficiency virus 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J. Infect. Dis. 179: 329-336.
47. + T cell responses associated with control of viremia. Science 278:1447-1450.
48. Tanguay, S., and J. J. Killion. 1994. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res. 13:259-263.
49. Tough, D. F., and J. Sprent. 1996. Viruses and T cell turnover: evidence for bystander proliferation. Immunol. Rev. 150:129-142.
50. Tsomides, T. J., A. Aldovini, R. P. Johnson, B. D. Walker, R. A. Young, and H. N. Eisen. 1994. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J. Exp. Med. 180:1283-1293.
51. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88:11276-11280.
52. Turner, S., M. E. Ellexson, H. D. Hickman, D. A. Sidebottom, M. Fernandez-Vina, D. L. Confer, and W. H. Hildebrand. 1998. Sequence-based typing provides a new look at HLA-C diversity. J. Immunol. 161:1406-1413.
53. Wolinsky, S. M., B. T. Korber, M. A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsel, M. R Furtado, Y. Cao, D. D. Ho, J. T. Safrit, and R. A. Koup. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542.
54. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
55. Zhang, L., B. Ramratnam, K. Tenner-Racz, Y. He, M. Vesanen, S. Lewin, A. Talal, P. Racz, A. S. Perelson, B. T. Korber, M. Markowitz, and D. D. Ho. 1999, Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
56. Zheng, L., X. Huang, Z. Fan, L. Borowski, C. C. Wilson, and C. R. Rinaldo, Jr. 1999. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res. Hum. Retrovir. 15:1011-1020.